MEDCO HEALTH SOLUTIONS INC
Consumer Discretionary · Retail-Drug Stores and Proprietary Stores · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | FY08 | FY07 | |
|---|---|---|---|---|---|
| Revenue | $70.06B | $65.97B | $59.80B | $51.26B | $44.51B |
| Operating income | $2.59B | $2.50B | $2.27B | $2.02B | — |
| Net income | $1.46B | $1.43B | $1.28B | $1.10B | $912.0M |
| Total assets | $16.96B | $17.10B | $17.92B | $17.01B | — |
| Total liabilities | $12.95B | $13.11B | $11.53B | $11.05B | — |
| Equity | $4.01B | $3.99B | $6.39B | $5.96B | $6.88B |
| EPS (diluted) | $3.62 | $3.16 | $2.61 | $2.13 | $1.63 |
| Shares out. | 404.5M | 464.1M | 490.0M | 518.6M | 560.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- 3.7%
- Net margin
- 2.1%
- Return on equity
- 36.3%
- Return on assets
- 8.6%
- Return on capital (ROCE)
- 31.5%
- Liabilities / assets
- 76.4%
- Debt / equity
- 3.23×
- Book value / share
- $9.91
- Revenue growth (YoY)
- 6.2%
- Net income growth (YoY)
- 2.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Altman Z″ (distress)
- 2.10grey zone
- Accruals / assets
- 1.0%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 5 good- High leverage (liabilities > 70% of assets)
- Altman Z″ in the grey zone
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Other material eventApr 6, 2012
- Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventApr 2, 2012
- Other material eventMar 28, 2012
- Other material eventMar 23, 2012
- Other material eventMar 12, 2012
- Results of operationsFeb 21, 2012
- Other material eventFeb 13, 2012
- Item 5.04Feb 13, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from MerckMRK · Aug 19, 2003
From the spin-off filings we track. Follow a company to walk its own history.